Merck Tbk (MERK) Fair Value & Analysis
Healthcare · ID · Market cap 1.7T IDR
Strengths
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 7 days ago
Share price −0.5% over the past month.
A strong business, screening 197% undervalued on our models.
What matters now
- The rarer combination: high quality (88/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (8,875 IDR). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 2,178 IDR – 4,267 IDR · fair‑value band 8,875 IDR – 14,577 IDR · the 3,980 IDR price screens below the 11,818 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Merck Tbk (MERK) currently trades at 3,980 IDR, while our model-based Fair Value estimate is 11,818 IDR, implying the stock looks roughly 196.9% undervalued today. The Quality Score stands at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Merck Tbk generated revenue of 1.3T IDR at a net margin of 23.3%. Revenue grew 31.6% year over year. It earns a return on equity of 31.8%. The balance sheet holds a net cash position of 350B IDR. Fundamentals as of Aug 13, 2026
Our scenario range runs from 8,875 IDR (bear case) to 14,577 IDR (bull case); at 3,980 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 58% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 197%, MERK screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (13,714 IDR) versus Asset-Based (1,459 IDR). Highest evidence: Residual Income (76).
Notify me when MERK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 85 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines.
Full company description
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research, development, production, and distribution of pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders, such as hypothyroidism. In addition, it is involved in the office/property leasing and management activities. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is based in Jakarta Timur, Indonesia. PT Merck Tbk operates as a subsidiary of Merck Holding GmbH.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Merck Tbk reported revenue of 1.2T IDR in FY2025 versus 1.1T IDR in FY2021, a compound +3.1%/yr. Reported net income was 244B IDR in FY2025, compounding +16.7%/yr from FY2021.
of which total revenue +1.2 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch MERK: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 638 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Merck Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Merck Tbk (MERK) overvalued or undervalued?
What is the fair value of MERK?
What is the quality score of MERK?
What is the revenue of Merck Tbk (MERK)?
What is the net profit margin of MERK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Merck Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.